{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390021990398799488.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.35772/ghm.2024.01080"}},{"identifier":{"@type":"URI","@value":"https://www.jstage.jst.go.jp/article/ghm/7/1/7_2024.01080/_pdf"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2025346099"}}],"dc:title":[{"@language":"en","@value":"Postoperative adjuvant chemotherapy in patients with gastric cancer based on the Nationwide Gastric Cancer Registry in Japan"}],"dc:language":"en","description":[{"type":"abstract","notation":[{"@language":"en","@value":"<p>The nationwide registry of the Japanese Gastric Cancer Association contains data related to the efficacy of adjuvant chemotherapy and prognostic factors across this patient population; elderly patients with advanced resectable gastric cancer are especially prevalent. Here, we analyzed data from 34,931 patients, who were treated between 2011 and 2013 at 421 hospitals in Japan. Although adjuvant chemotherapy was effective overall, 75 years or older elderly patients had a worse prognosis compared to younger patients. The most administered adjuvant chemotherapy was S-1 monotherapy. Adjuvant S-1 monotherapy was also effective for patients with pT1N2, pT1N3, and pT3N0 stage II tumors, as well as patients with other stage II and III malignancies. Independent prognostic factors for poor overall and relapse-free survival in patients at both stage II and stage III were age 75 or older, male, preoperative Eastern Cooperative Oncology Group performance status (ECOG-PS) 1 or more, preoperative renal dysfunction, undifferentiated adenocarcinoma, undergoing total gastrectomy, open laparotomy, no adjuvant chemotherapy, D1 lymphadenectomy, residual tumor R1 or R2, and Clavien-Dindo classification grade II or higher. Age 75 or older, renal dysfunction, ECOG-PS 1 and total gastrectomy were also significant risk factors for postoperative complications and lower compliance with adjuvant chemotherapy. Our analysis also revealed that adjuvant chemotherapy after resection of cancer of gastric remnant and postoperative chemotherapy against CY1 gastric cancer were also effective. We conclude that adjuvant chemotherapy is effective for all stage II and III patients including age 75 or older gastric cancer patients, in addition to distal gastrectomy, proximal gastrectomy, and pylorus-preserving surgery to avoid total gastrectomy may improve surgical outcomes and quality of life for elderly patients. </p>"}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410021990398799488","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Yamada Yasuhide"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Medical Research, National Center for Global Health and Medicine, Tokyo, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1410021990398799504","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Seto Yasuyuki"}],"jpcoar:affiliationName":[{"@language":"en","@value":"National Cancer Center Hospital, Tokyo, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1410021990398799496","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Yoshikawa Takaki"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1410021990398799501","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Takeuchi Hiroya"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Surgery, Hamamatsu University, School of Medicine, Hamamatsu, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1410021990398799505","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Kitagawa Yuko"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Surgery, Keio University, School of Medicine, Tokyo, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1410021990398799490","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Kodera Yasuhiro"}],"jpcoar:affiliationName":[{"@language":"en","@value":"NHO Nagoya Medical Center, Nagoya, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1410021990398799497","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Doki Yuichiro"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Osaka University, Osaka, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1410021990398799491","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Yoshida Kazuhiro"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Gifu University, Gifu, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1410021990398799494","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Muro Kei"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Pharmacotherapy, Aichi Cancer Center, Nagoya, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1410021990398799500","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Kabeya Yoshinori"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Healthcare & Life Sciences, IBM Japan, Ltd, Tokyo, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1410021990398799493","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Kamada Ami"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Healthcare & Life Sciences, IBM Japan, Ltd, Tokyo, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1410021990398799499","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Nagashima Kengo"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1410021990398799498","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Kumamaru Hiraku"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Healthcare Quality Assessment, The University of Tokyo Graduate School of Medicine, Tokyo, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1410021990398799492","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Tachimori Hisateru"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Health Policy and Management, Keio University School of Medicine, Tokyo, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1410021990398799502","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Sasako Mitsuru"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Yodogawa Christian Hospital, Osaka, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1410021990398799503","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Katai Hitoshi"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Tachikawa Hospital, Tokyo, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1410021990398799495","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Konno Hiroyuki"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Hamamatsu University, School of Medicine, Hamamatsu, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1410021990398799489","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Kakeji Yoshihiro"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Database Committee, The Japanese Society of Gastroenterological Surgery, Tokyo, Japan."},{"@language":"en","@value":"Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan."}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"24349186"},{"@type":"EISSN","@value":"24349194"}],"prism:publicationName":[{"@language":"en","@value":"Global Health & Medicine"},{"@language":"ja","@value":"Global Health & Medicine"},{"@language":"en","@value":"GHM"}],"dc:publisher":[{"@language":"en","@value":"National Center for Global Health and Medicine"},{"@language":"ja","@value":"国立研究開発法人 国立国際医療研究センター"}],"prism:publicationDate":"2025-02-28","prism:volume":"7","prism:number":"1","prism:startingPage":"13","prism:endingPage":"27"},"reviewed":"false","url":[{"@id":"https://www.jstage.jst.go.jp/article/ghm/7/1/7_2024.01080/_pdf"},{"@id":"https://search.jamas.or.jp/link/ui/2025346099"}],"availableAt":"2025-02-28","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=stomach%20cancer","dc:title":"stomach cancer"},{"@id":"https://cir.nii.ac.jp/all?q=lavage%20cytology","dc:title":"lavage cytology"},{"@id":"https://cir.nii.ac.jp/all?q=elderly%20patient","dc:title":"elderly patient"},{"@id":"https://cir.nii.ac.jp/all?q=S-1","dc:title":"S-1"},{"@id":"https://cir.nii.ac.jp/all?q=surgical%20site%20infection","dc:title":"surgical site infection"},{"@id":"https://cir.nii.ac.jp/all?q=postoperative%20complication","dc:title":"postoperative complication"},{"@id":"https://cir.nii.ac.jp/all?q=Clavien-Dindo","dc:title":"Clavien-Dindo"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360011144383776768","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Surgical site infection risk factors identified by multivariate analysis for patient undergoing laparoscopic, open colon, and gastric surgery"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021800603035776","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021800604324864","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sex and Gender Differences in Bacterial Infections"}]},{"@id":"https://cir.nii.ac.jp/crid/1360282589191213184","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285707904419584","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620524573184","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Effect of Food on the Pharmacokinetics of S-1 after Single Oral Administration to Patients with Solid Tumors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294645158611456","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298761964604800","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302175424755072","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Optimal extent of lymph node dissection for remnant advanced gastric carcinoma after distal gastrectomy: a retrospective analysis of more than 3000 patients from the nationwide registry of the Japanese Gastric Cancer Association"}]},{"@id":"https://cir.nii.ac.jp/crid/1360303275731284352","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Low Maruyama Index Surgery for Gastric Cancer: Blinded Reanalysis of the Dutch D1‐D2 Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360303275732095616","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Current role of surgery and multimodal treatment in localized gastric cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360303275732596224","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Identifying Risk Factors of Complications following Total Gastrectomy for Gastric Cancer: Comparison between Splenectomy and Spleen-Preserving Surgery – A Supplementary Analysis of JCOG0110"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181249960960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567186827611904","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584346983711872","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Extended lymphadenectomy in elderly and/or highly co-morbid gastric cancer patients: A retrospective multicenter study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584750017175296","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584750018934272","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Mortality and Morbidity and Disease Free Survival after D1 and D2 Gastrectomy for Stomach Adenocarcinomas"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570149700736","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Alternative pharmacokinetics of S‐1 components, 5‐fluorouracil, dihydrofluorouracil and α‐fluoro‐β‐alanine after oral administration of S‐1 following total gastrectomy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570418194176","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861711920541440","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360864114055613696","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries"}]},{"@id":"https://cir.nii.ac.jp/crid/1360866223605165952","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Risk factors for surgical site infection in patients with gastric cancer: A meta‐analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360866225176857728","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Improved regional control and survival with “low Maruyama Index” surgery in gastric cancer: autopsy findings from the Dutch D1-D2 Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360866225176858880","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360866225176860416","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Development of a reliable surgical quality assurance tool for gastrectomy in oncological trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1360866225177481088","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044191523968","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045314185856","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Computer analysis in making preoperative decisions: A rational approach to lymph node dissection in gastric cancer patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045373723520","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045868457088","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995426806912","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945708812288","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945751771008","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nodal dissection for patients with gastric cancer: a randomised controlled trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418387980032","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894414685952","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369141629952","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Risk Factors for Poor Compliance with Adjuvant S-1 Chemotherapy for Gastric Cancer: A Multicenter Retrospective Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845441165312","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845592961152","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845625575552","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670318526008576","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319293209344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prognostic significance of peritoneal lavage cytology in staging gastric cancer: systematic review and meta-analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319565089664","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670321053126784","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268985128832","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269669510528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Risk Factors for the Loss of Lean Body Mass After Gastrectomy for Gastric Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1520291855663043712","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-term follow up of patients who were positive for peritoneal lavage cytology : final report from the CCOG0301 study"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:2013909854"},{"@type":"CROSSREF","@value":"10.35772/ghm.2024.01080"}]}